NASDAQ:IBIO
iBio, Inc.
iBio, Inc.'s revenue fell 75.0% in fiscal 2026 to $100,000 while operating margin fell to −35141.0%, its lowest in 3 years. Free cash flow was −$23.8M, −23796.0% of revenue, and the diluted share count rose 891.1%.Summary generated from iBio, Inc.'s SEC filings. Latest annual report filed Aug 28, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$100,000
Revenue growth−75.0%
Revenue, 5-yr CAGR−46.9%
Gross marginn/a
Operating margin−35141.0%
Net margin−33044.0%
ROICn/a
Return on equity−65.7%
Debt / equityn/a
Free cash flow−$23.8M
FCF margin−23796.0%
Share count change+891.1%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 2 | 0 | 0 | 0 | 0 |
| Operating income | −30 | −29 | −17 | −19 | −35 |
| Net income | −50 | −65 | −25 | −18 | −33 |
| Free cash flow | −45 | −36 | −19 | −15 | −24 |
Recent filings
- 8-KRegulation FD disclosure
Sep 14, 2026 - DEF 14AProxy statement
Sep 4, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Aug 28, 2026 - 8-KResults of operations and financial condition
Aug 28, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KDirector or officer change
Aug 4, 2026 - 8-KOther events
Jul 17, 2026 - 8-KRegulation FD disclosure
Jul 1, 2026